Keyword: Richard Gonzalez
With resolutions on the ballot at six top U.S. drugmakers, investors aim to learn how drug pricing affects executive pay.
AbbVie and Shire investors struck an agreement to settle claims AbbVie misled the public about its reasons for pursuing Shire.
AbbVie investors are calling for a separation of powers between its board chairman and CEO roles following congressional scrutiny and patent fights over its drug Humira.
AbbVie's in need of a Humira follow-up, and it took one step in that direction with a Japanese approval for IL-23 inhibitor Skyrizi.
AbbVie helmsman Richard Gonzalez's 2018 pay was still partly tied to Humira sales. And he still scored more than $20 million.
Once the Senate finance committee’s drug pricing hearing started on Tuesday, it didn’t take long for sparks to fly.
Humira was only a couple million dollars away from its $20 billion sales goal for 2018, but 2019 will be worse, say AbbVie executives.
Effective immediately, AbbVie is streamlining its executive team to four managers who will serve under CEO Richard Gonzalez.
Boehringer is hoping for big things from its Humira biosimilar in the U.S.—so much so that it’s giving up on copycat biologics in other countries.